- Lobbying
- mcmanus AND group
Lobbying Arrangements Results for 'Mcmanus Group'
Former Covered Federal Workers:
Other Lobbyists:
Issue | Client | Firm | Lobbyists | Start Date | Latest Filing Date |
---|---|---|---|---|---|
Details |
PFIZER, INC
|
THE MCMANUS GROUP | |||
Details Medicare coverage and reimbursement. |
Breathe Technologies Inc.
|
THE MCMANUS GROUP | |||
Details Legislation and regulation affecting health risk assessments. |
Matrix Medical Network
|
THE MCMANUS GROUP | |||
Details Increased access to narcoleptic medication (S.574/H.R.4692 - Increasing Prescription Drug Competition Act) |
Avadel Pharmaceuticals
|
THE MCMANUS GROUP | |||
Details H.R.7188 - Shandra Eisenga Human Cell and Tissue Product Safety Act H.R.6705 - Effective Screening and Testing for Tuberculosis Act Issues related to Human Cellular Tissue Products (HCTP) |
VIVEX Biologics
|
THE MCMANUS GROUP | |||
Details H.R. 3590, the Patient Protection and Affordable Care Act H.R. 4872, Reconciliation Act |
Conservatives for Patients Rights, Inc
|
Mr. Brian McManus | |||
Details Medicare and Medicaid reimbursement |
Allergan Inc.
Biotechnology and specialty pharmaceutical product manufacturer |
THE MCMANUS GROUP | |||
Details Advanced molecular diagnostic policy. Laboratory and pathology coverage and payment issues. |
Caris Life Sciences, Inc.
|
THE MCMANUS GROUP | |||
Details Opposition to medical device industry tax in P.L. 111-148, "Patient Protection and Affordable Care Act," and P.L. 111-152, "Reconciliation Act of 2010." FDA approval and enforcement issues. |
Volcano Corporation
|
THE MCMANUS GROUP | |||
Details Issues related to access to and development of domestic rare mineral resources. |
Red Flat Nickel Corporation
|
THE MCMANUS GROUP | |||
Details Education and advocacy regarding pediatric and rare disease programs at the FDA. |
XOMA Corporation
|
THE MCMANUS GROUP | |||
Details Development of policies to advance the antimicrobial research and development environment. Support of H.R.512 - DISARM Act of 2015 language in - H.R.6 - 21st Century Cures Act. |
Johnson & Johnson
|
The McManus Group, DBA Antimicrobial Innovation Alliance | |||
Details Medicare reimbursement for radiation oncology treatment. MACRA Implementation (PL No: 114-10) |
Radiation Therapy Alliance
|
THE MCMANUS GROUP | |||
Details Development of policies to advance the antimicrobial research and development environment. Support of H.R.512 - DISARM Act of 2015 language in - H.R.6 - 21st Century Cures Act. |
AstraZeneca
|
The McManus Group, DBA Antimicrobial Innovation Alliance | |||
Details Education and awareness related to COVID-19 therapeutics. Issues related to H.R.4421 Preparing for All Hazards and Pathogens Reauthorization Act and S.2333 - Pandemic and All-Hazards Preparedness ... |
Invivyd (formerly known as Adagio Therapeutics))
|
THE MCMANUS GROUP | |||
Details Implementation of provisions included in Subtitle BB of PL. 116-260 - No Surprises Act. |
Pediatrix Medical Group (MEDNAX National Medical Group)
|
THE MCMANUS GROUP | |||
Details Development of policies to advance the antimicrobial research and development environment. Support of H.R.512 - DISARM Act of 2015 language in - H.R.6 - 21st Century Cures Act. |
The Medicines Company
|
The McManus Group, DBA Antimicrobial Innovation Alliance | |||
Details Sec. VII of the proposed rule for the Durable Medical Equipment, Prosthetics, Orthotics, and Supplies Competitive Bidding Program for Calendar Year 2019 (RIN 0938-AT28). |
American Lung Association
|
THE MCMANUS GROUP | |||
Details Regulatory and legislative activities regarding 340B program. Access and reimbursement issues in Medicare Part D. |
ELI LILLY AND COMPANY
|
THE MCMANUS GROUP | |||
Details Development of policies to advance the antimicrobial research and development environment. Support of H.R.512 - DISARM Act of 2015 language in - H.R.6 - 21st Century Cures Act. |
Zavante Therapeutics, Inc.
|
The McManus Group, DBA Antimicrobial Innovation Alliance | |||
Details Development of policies to advance the antimicrobial research and development environment. Support of H.R.512 - DISARM Act of 2015" language in - H.R.6 - 21st Century Cures Act. |
Merck & Co., Inc.
Client manufacturers and develops pharmaceuticals, vaccines and biologic therapies. |
The McManus Group, DBA Antimicrobial Innovation Alliance | |||
Details Medicare benefit cost sharing. |
Gary and Mary West Health Institute
|
THE MCMANUS GROUP | |||
Details Support for Medicare coverage of prostate cancer diagnostic test in H.R. 2371, the HEARTS Act of 2019, H.R. 3429, the HEARTS and Rural Relief Act, and H.R. 1865, the Further Consolidated Appropriat... |
Strand Diagnostics
|
THE MCMANUS GROUP | |||
Details H.R. 2520/S. 1465, "To amend title XVIII of the Social Security Act to provide for coverage under the Medicare Program of certain medical mobility devices approved as class III medical devices." H.... |
DEKA RESEARCH & DEVELOPMENT CORPORATION
|
THE MCMANUS GROUP | |||
Details Development of policies to advance the antimicrobial research and development environment. Support of H.R.512 - DISARM Act of 2015 language in - H.R.6 - 21st Century Cures Act. |
Spero Opco, Inc.
|
The McManus Group, DBA Antimicrobial Innovation Alliance | |||
Details Development of policies to advance the antimicrobial research and development environment. Support of H.R.512 - DISARM Act of 2015 language in - H.R.6 - 21st Century Cures Act. |
Astellas Pharma US, Inc.
|
The McManus Group, DBA Antimicrobial Innovation Alliance | |||
Details Medicare coverage and reimbursement for negative pressure wound therapy devices. CMS rule RIN 0938-AR10 regarding hospital outpatient departments and CMS rule RIN 0938AR11 regarding physician fee ... |
Spiracur Inc.
|
THE MCMANUS GROUP | |||
Details DoD Authorizations and Appropriations |
PRECISION REMOTES, INC
|
THE SPECTRUM GROUP | |||
Details 2012 Appropriations and Authorizations |
CPU TECHNOLOGY
|
THE SPECTRUM GROUP | |||
Details Medicare coverage and reimbursement |
The McManus Group on behalf of Caris Life Sciences and Breathe Technologies Inc.
Government affairs consulting |
WALTER CONSULTING | |||
Details Development of policies to advance the antimicrobial research and development environment. Support of H.R.512 - DISARM Act of 2015" language in - H.R.6 - 21st Century Cures Act. |
Allergan, Plc.
Allergan is a diversified global pharmaceutical company |
The McManus Group, DBA Antimicrobial Innovation Alliance | |||
Details Development of policies to advance the antimicrobial research and development environment. Support of H.R.512 - DISARM Act of 2015 language in - H.R.6 - 21st Century Cures Act. |
Tetraphase Pharmaceuticals
|
The McManus Group, DBA Antimicrobial Innovation Alliance | |||
Details Development of policies to advance the antimicrobial research and development environment. Support of H.R.512 - DISARM Act of 2015 language in - H.R.6 - 21st Century Cures Act. |
Microbion Corporation
|
The McManus Group, DBA Antimicrobial Innovation Alliance | |||
Details Development of policies to advance the antimicrobial research and development environment. Support of H.R.512 - DISARM Act of 2015 language in - H.R.6 - 21st Century Cures Act. |
GlaxoSmithKline
|
The McManus Group, DBA Antimicrobial Innovation Alliance | |||
Details Medicare reimbursement and requirements for vascular access in dialysis. H.R. 3962, "Affordable Health Care for America Act," and H.R. 3590, "Patient Protection and Affordable Care Act." CMS-1418-P... |
TRANSONIC SYSTEMS
|
THE MCMANUS GROUP | |||
Details MACRA Implementation (81 FR 28161). Opposition to Part B Demo (81 FR 13229) Issues relating to Opioid abuse. Increased funding for treatment of Opioid addiction. HR 953 & S. 524: Comprehensive Addi... |
AMERICAN MEDICAL ASSOCIATION
|
THE MCMANUS GROUP | |||
Details Medicare Parts B and D drugs payments and access. |
ALLERGAN, INC.
|
THE MCMANUS GROUP | |||
Details Access and reimbursement of drugs in Medicare Parts B and D. Implementation of provisions included in Subtitle B of PL. 117-169 - Inflation Reduction Act of 2022 Issues related to reforming and i... |
Gilead Sciences, Inc.
|
THE MCMANUS GROUP | |||
Details Advocated for access to abuse-deterrent formulations. Support for H.R. 5582 - Abuse Deterrent Access Act of 2018. |
Egalet US Inc.
|
THE MCMANUS GROUP | |||
Details Pharmaceutical coverage and access in Parts A, B, C, and D. S. 2543, the Prescription Drug Pricing Reduction Act and H.R. 3, the Lower Drug Costs Now Act. Advocacy regarding access to 340B reimburs... |
Novartis
|
THE MCMANUS GROUP | |||
Details Implementation of provisions included in Subtitle B of PL. 117-169 - Inflation Reduction Act of 2022 Access and coverage of inpatient drugs in Medicaid program (H.R. 2666- Medicaid VBPs for Patien... |
PTC Therapeutics Inc.
|
THE MCMANUS GROUP | |||
Details General health care coverage and reimbursement; issues related to infectious disease drug development and procurement; legislative and regulatory issues related to biodefense countermeasure develop... |
Achaogen
|
THE MCMANUS GROUP | |||
Details Development of policies to advance the antimicrobial research and novel product development environment, including advancing new market incentives. Medicare payment for inpatient antibiotics. |
Antimicrobial Innovation Alliance
|
THE MCMANUS GROUP | |||
Details Education and advocacy regarding emergency services and Medicare reimbursement of freestanding emergency centers including H.R.1694 - Emergency Care Improvement Act. Implementation of provisions in... |
National Association of Freestanding Emergency Centers (NAFEC)
|
THE MCMANUS GROUP | |||
Details Education and advocacy regarding drug distribution. H.R. 1038 / S.413 - Improving Transparency and Accuracy in Medicare Part D Spending Act. H.R. 1316 - Prescription Drug Price Transparency Act. Su... |
National Association of Specialty Pharmacy (NASP)
|
THE MCMANUS GROUP | |||
Details Support for research, education, and prevention activities relating to nonalcoholic steatohepatitis. Policies regarding research, education, and prevention activities relating to nonalcoholic steat... |
NASH Alliance LLC
|
THE MCMANUS GROUP | |||
Details Access and coverage of inpatient drugs in H.R. 2666 - Medicaid VBPs for Patients (MVP) Act. Education and awareness of rare and ultra rare diseases and patient access to orphan drugs. Education an... |
Orchard Therapeutics North America
|
THE MCMANUS GROUP | |||
Details Access and reimbursement in Medicare Parts B & D. Implementation of provisions included in Subtitle B of PL. 117-169 - Inflation Reduction Act of 2022. Issues related to the reauthorization of th... |
Alkermes, Inc.
|
THE MCMANUS GROUP | |||
Details Medicare issues as they relate to oncology and multi-cancer early detection, including diagnostics and screening, H.R.2407 - Nancy Gardner Sewell Medicare Multi-Cancer Early Detection Screening Cov... |
GRAIL, INC.
|
THE MCMANUS GROUP | |||
Details S.1050, H.R.1588, H.R.2858 |
AmTech Corporation
Defense |
THE SPECTRUM GROUP |